To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers.
introduction
The efficacy of the oral fluoropyrimidine capecitabine (XelodaÒ; F. Hoffmann-La Roche, Basle, Switzerland) in gastrointestinal cancers has been investigated in a series of six phase III non-inferiority trials. In the mid-1990s, capecitabine was compared with 5-fluorouracil/folinic acid (5-FU/FA; Mayo Clinic regimen) in two identical randomised trials in patients with previously untreated metastatic colorectal cancer [1, 2] , and later as adjuvant therapy in patients with resected stage III colon cancer [3] . More recently, capecitabine in combination with oxaliplatin (XELOX) was compared with 5-FU/FA plus oxaliplatin (FOLFOX4) as first-line [4] and second-line [5] treatment of patients with metastatic colorectal cancer; the design of the first-line trial was later modified to a 2 · 2 factorial design to further compare the addition of bevacizumab versus placebo to oxaliplatin-based chemotherapy [6] . In patients with advanced gastric cancer, capecitabinecisplatin was compared with 5-FU-cisplatin as first-line therapy in a randomised phase III non-inferiority trial [7] . In all of these trials, the efficacy of capecitabine-containing chemotherapy was found to be at least equivalent to that of the 5-FU/FA-containing comparator regimen [1] [2] [3] [4] [5] 7] . The consistency of these findings suggests that capecitabine may be a suitable alternative for 5-FU/FA in cancers for which standard treatment involves fluoropyrimidine-based chemotherapy.
In all of these studies, a surrogate measure for overall survival was used as the primary efficacy end point. The studies were, therefore, not powered to show non-inferiority for overall survival, the benchmark of efficacy in cancer patients. With this in mind, we conducted a meta-analysis to allow the effects of treatment on overall survival to be estimated with greater statistical power. The present paper describes a post hoc meta-analysis of the six phase III clinical trials described above, which was requested by European regulatory authorities and evaluated the non-inferiority of capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy in terms of overall survival in gastrointestinal cancers. outcome measure
Overall survival was defined as the time from randomisation until death from any cause. Living patients were censored at the time of last available follow-up.
statistical analysis
Analyses were carried out on an intent-to-treat basis, i.e. all randomised patients were included according to their allocated treatment. Data were pooled according to assigned treatment, such that the capecitabine arm included patients who received single-agent capecitabine, XELOX 6 bevacizumab or capecitabine-cisplatin, and the 5-FU arm included patients who received 5-FU/FA, FOLFOX4 6 bevacizumab or 5-FU-cisplatin.
Overall survival was analysed according to Kaplan-Meier estimates. The results were presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and stratified by trial. Individual study data were presented as forest plots. A multivariate analysis was carried out to test for the effects of prognostic factors (i.e. age, gender and baseline ECOG performance score) on overall survival using Cox's proportional hazards model and presented as stratified and unstratified analyses.
results

description of studies
Six randomised studies involving a total of 6171 patients with stage III colon cancer (n = 1987), metastatic colorectal cancer (n = 3868) or advanced gastric cancer (n = 316) were included in the meta-analysis. A total of 3097 patients were treated with capecitabine-containing chemotherapy and 3074 patients with 5-FU 6 FA-containing chemotherapy.
Details of these studies, including the patient population, treatment regimens and the number of patients, are presented in Table 1 .
overall survival
The unadjusted analysis of overall survival for the six trials grouped according to tumour type (i.e. stage III colon cancer, metastatic colorectal cancer or advanced gastric cancer) is presented in Table 2 . The respective Kaplan-Meier curves are shown in Figure 1 .
In study M66001, which compared single-agent capecitabine versus 5-FU/FA (Mayo Clinic regimen) as adjuvant therapy in patients with resected stage III colon cancer, the HR for overall survival was 0.86 (95% CI 0.74-1.01). For studies SO14695 and SO14796, which compared single-agent capecitabine versus 5-FU/FA (Mayo Clinic regimen) as firstline therapy in patients with metastatic colorectal cancer, the HR for overall survival was 0.95 (95% CI 0.84-1.06). For studies NO16966 and NO16967, which compared XELOX 6 bevacizumab versus FOLFOX4 6 bevacizumab as first-or second-line therapy in patients with metastatic colorectal cancer, the HR for overall survival was 0.97 (95% CI 0.89-1.05). And for study ML17032, which compared capecitabinecisplatin versus 5-FU-cisplatin as first-line therapy in patients with advanced gastric cancer, the HR for overall survival was 0.85 (95% CI 0.65-1.11).
The results of the unadjusted meta-analysis of overall survival for the pooled treatment groups stratified by study are presented in Table 2 and Figure 2 . The unadjusted HR for overall survival for capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy was 0.94 (95% CI 0.89-1.00; P = 0.0489).
multivariate analysis
In the planned multivariate analysis, both female gender and a good baseline ECOG performance status (i.e. 0) were significant prognostic factors for an improved overall survival in the unstratified analysis regardless of the treatment assigned (Table 3) . ECOG performance status alone was a significant prognostic factor for improved overall survival, regardless of the treatment assigned in the analysis stratified by study (Table 3) . discussion Capecitabine, either alone or as part of a combination regimen, has been compared with 5-FU-based regimens in a series of phase III non-inferiority trials in patients with gastrointestinal cancers. In each of the studies, recognised surrogate measures of overall survival were selected as the primary study end point, i.e. objective response rate, progression-free survival or diseasefree survival [8] [9] [10] [11] [12] [13] . However, overall survival remains the most clinically meaningful measure of treatment effect in patients with cancer. The present meta-analysis combined individual data from >6000 patients from each of these trials so that treatment effect, in terms of overall survival, could be evaluated with greater statistical power. The final result shows that capecitabine-containing chemotherapy is at least equivalent to 5-FU-containing chemotherapy in terms of overall survival in the treatment of gastrointestinal cancers. A multivariate analysis supported this result and suggests that the findings are robust.
The patient population included in the present meta-analysis was clearly heterogeneous, i.e. patients with stage III colon cancer, metastatic colorectal cancer and advanced gastric cancer. Therefore, we also analysed overall survival by cancer type and showed that, for each of these patient subsets, capecitabine-containing chemotherapy had similar or slightly better efficacy than 5-FU-containing chemotherapy (HR 0.85-0.97). The consistency of these findings with the overall meta-analysis result suggests that the non-inferiority of Most of the patients included in the meta-analysis had either colon or colorectal cancer (95%). The dataset for patients with advanced gastric cancer was considerably smaller (n = 316). While not included in our analysis, the recent REAL2 study also compared the efficacy of capecitabine versus 5-FU as part of epirubicin/platinum-based triple therapy in patients with advanced oesophagogastric cancer [14] . Pooled data from capecitabine-based triplet regimens (epirubicin, cisplatin, xeloda + epirubicin, oxaliplatin, xeloda; n = 480) showed significant non-inferiority to the pooled 5-FU-based triplets (epirubicin, cisplatin, fluorouracil + epirubicin, oxaliplatin, fluorouracil; n = 484) in terms of median overall survival (10.9 versus 9.6 months; HR 0.86, 95% CI 0.80-0.99; primary end point); the upper limit of the 95% CI for the HR was below the predefined value of 1.23. Data from REAL2 and ML17032 have recently been combined in a separate meta-analysis, which showed that overall survival was superior in patients treated with capecitabine-containing combinations (n = 654) compared with patients treated with 5-FU-containing combinations (n = 664) (HR = 0.87; 95% CI 0.77-0.98, P = 0.02) [15] .
The most recent studies involving capecitabine to have been completed are comparisons of capecitabine-oxaliplatin and 5-FU/FA-oxaliplatin regimens in metastatic colorectal cancer. Two of the clinical studies addressing this question, NO16966 and NO16967, were considered in the present analysis. The subset analysis of these two studies suggests that the two regimens have similar efficacy (HR = 0.97). However, many original article Annals of Oncology other phase II and III studies comparing capecitabine-and 5-FU/FA-oxaliplatin, which were not included in the present analysis, have been carried out. It is therefore of interest that two other meta-analyses specifically addressing this question are supportive of the present analysis. Cassidy et al. [16] carried out a meta-analysis of seven phase II and III trials (n = 2826) comparing capecitabine-oxaliplatin with 5-FU/FA-oxaliplatin regimens in metastatic colorectal cancer and reported an HR of 1.02 (95% CI 0.95-1.12) for overall survival. Arkenau et al. [17] also reported similar findings in another meta-analysis of six randomised trials with regard to overall survival (n = 3494; HR = 1.04, 95% CI 0.95-1.12).
Strengths of the present analysis are that it was based on individual patient data taken from well-designed, prospective Annals of Oncology original article multinational trials. A limitation of our analysis was that it was not a systematic review of the medical literature, but rather an analysis of trials in the manufacturer's database. Some inclusion bias, as discussed above, is inevitable with this method of trial selection. Although we did not perform a test of heterogeneity, both stratified and unstratified analyses showed similar results which can be taken as evidence that there was no heterogeneity. It should also be noted that this analysis was designed specifically to look at a single end point, overall survival. It cannot be assumed that the findings can be generalised to other efficacy end points, e.g. tumour response rate.
In conclusion, oral capecitabine is at least equivalent to i.v. 5-FU in terms of overall survival in patients with colorectal or gastric cancers; clinicians can, therefore, use these agents interchangeably in these patient populations. 
